血友病A的基因治疗:成本效果分析
研究采用Markov状态转换模型,从美国医疗系统角度比较重型血友病A基因治疗与凝血因子Ⅷ(FVIII)预防治疗的成本与效果,以质量调整生命年(QALY)为效果指标。概率敏感性分析中基因治疗在92%的模型迭代中占优。
要点
- 概率敏感性分析中同时变化所有参数3000次,基因治疗在92%的模型迭代中占优。
核心结论
- 与FVIII预防治疗相比,基因治疗重型血友病A可能节约成本或具有成本效果。
研究设计与样本
- 研究建立Markov状态转换模型,从美国医疗系统角度估算重型血友病A治疗策略的成本与效果。
- 基础病例为假设的30岁患者队列,分别接受基因治疗或FVIII预防治疗。
- 效果指标为质量调整生命年(QALY),模型概率与效用值来自文献,成本来自Medicare报销数据。
- 研究进行单因素敏感性分析和概率敏感性分析以检验结果的稳健性。
主要发现
- 基因治疗占优预防治疗,即成本更低且效果更好。
- 其他所有参数在临床合理范围内变化时结果不敏感;概率敏感性分析中同时变化所有参数3000次,基因治疗在92%的模型迭代中占优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene therapy provides a potential phenotypic cure for hemophilia, yet the cost of this novel treatment is high, tempering enthusiasm and raising questions regarding cost vs benefit. To evaluate the cost-effectiveness of gene therapy treatment of severe hemophilia A compared with prophylaxis with factor VIII (FVIII), we developed a Markov state-transition model to estimate the costs and effectiveness of severe hemophilia A treatment strategies from a United States health care system perspective. Quality-adjusted life-years (QALYs) were the effectiveness measure. In the base case, hypothetical cohorts of 30-year-old patients received gene therapy or FVIII prophylaxis. We obtained model probabilities and utilities from the literature and costs from Medicare reimbursement data. One-way and probabilistic sensitivity analyses were performed to test the robustness of results. Over a 10-year time horizon, total per-person gene therapy strategy costs were $1.0M and resulted in 8.33 QALYs, whereas prophylaxis cost $1.7M and resulted in 6.62 QALYs. Thus, gene therapy dominated prophylaxis (costs less and was more effective). Gene therapy remained dominant unless initial costs exceeded $1.6M and were <$100 000 per 1 QALY gained compared with prophylaxis if initial costs were <$1.7M. Results were not sensitive to variation of all other parameters over clinically plausible ranges. In a probabilistic sensitivity analysis simultaneously varying all parameters 3000 times over parameter distributions, gene therapy was dominant in 92% of model iterations. Treatment of severe hemophilia A with gene therapy is likely to be cost-saving or cost-effective compared with FVIII prophylaxis.
引用
- Machin N, Ragni MV, Smith KJ, et al. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018. PMID: 30042145. doi:10.1182/bloodadvances.2018021345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。